

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE A PROSPECTUS OR OFFERING MEMORANDUM OR AN OFFER FOR SALE OR SUBSCRIPTION IN RESPECT OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS INCORPORATED INTO UK LAW BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

3 July 2025



**CRISM Therapeutics Corporation**  
("CRISM", "CRISM Therapeutics" or the "Company")

**Result of Retail Offer and Additional Placing**

Further to the announcement by the Company in respect of the Retail Offer dated 30 June 2025, CRISM Therapeutics Corporation announces that, following the closing of the Retail Offer on the BookBuild platform on 2 July 2025, the Company has raised gross proceeds of £54,021 (the "**Retail Offer**") by way of a subscription of 450,176 Retail Offer Shares at the Issue Price of 12 pence per share.

In parallel with the Retail Offer, the Company announces an additional placement of 166,666 new ordinary shares of no par value each in the Company ("**Additional Placing Shares**") at the Issue Price to raise gross proceeds of £20,000 (the "**Additional Placing**"), to an existing shareholder who was unable to participate in the Retail Offer. The gross proceeds of the Placing, the Additional Placing and the Retail Offer raised, in aggregate, £874,021.

The proceeds of the Retail Offer and Additional Placing, together with the Placing announced on 30 June 2025 (together the "**Proceeds**"), will enable the Company to continue to progress the development of ChemoSeed. Specifically, the Proceeds will fund CRISM for GMP manufacture of a clinical trial batch of ChemoSeed, through the MHRA's Clinical Trial Authorisation approval process and to first patients dosed in CRISM's registration grade Phase 2 clinical trial in early 2026.

**Admission and Total Voting Rights**

Application has been made to the London Stock Exchange for admission of the Retail Offer Shares and Additional Placing Shares ("**Admission**"). It is expected that Admission will become effective and that trading will commence in the Placing Shares at 8.00 a.m. on or around 8 July 2025, or such later date as may be agreed between the Company and SP Angel. The Retail Offer Shares and Additional Placing Shares will rank *pari passu* with the Company's existing ordinary shares.

Following Admission, the total issued share capital of the Company will consist of 39,961,822 ordinary shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company is 39,961,822 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Other than where defined, capitalised terms used in this Announcement have the meanings given to them in the announcements of 30 June 2025.

-Ends-

**Enquiries:**

**Company**  
CRISM Therapeutics  
Corporation  
Andrew Webb, CEO

**Nomad and Broker**  
S.P. Angel Corporate Finance LLP  
Richard Morrison / Adam Gault

**Financial PR**  
Burson Buchanan  
Mark Court / Jamie Hooper

Andrew Webb, CEO  
Chris McConville, CSO  
via Burson Buchanan

Richard Morrison / Adam Cowi  
Vadim Alexandre / Rob Rees  
+44 (0) 20 3470 0470

Mark Court / Jamie Hooper  
CRISM@buchanancomms.co.uk  
+44 (0) 20 7466 5000

#### About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: <https://www.crismtherapeutics.com/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROISSESEEISEDW